Provexis (FRA:NZCA) Common Stock : €2.57 Mil (As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Provexis Common Stock?

Provexis's quarterly common stock declined from Sep. 2022 (€2.54 Mil) to Mar. 2023 (€2.51 Mil) but then increased from Mar. 2023 (€2.51 Mil) to Sep. 2023 (€2.57 Mil).

Provexis's annual common stock increased from Mar. 2021 (€2.58 Mil) to Mar. 2022 (€2.65 Mil) but then declined from Mar. 2022 (€2.65 Mil) to Mar. 2023 (€2.51 Mil).

Provexis Common Stock Historical Data

The historical data trend for Provexis's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis Common Stock Chart

Provexis Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Common Stock

Get a 7-Day Free Trial

2.31

2.58

2.65

2.51

Provexis Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Common Stock	Get a 7-Day Free Trial															2.58	2.65	2.54	2.51	2.57

Provexis Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Provexis (FRA:NZCA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (FRA:NZCA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

PXS.GB:UK PXS:UK

Address

2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ

Website

https://www.provexis.com

Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.

Provexis (FRA:NZCA) Headlines

No Headlines